UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2008

NEOSTEM, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-10909	22-2343568
(State Or Other Jurisdiction Of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

420 Lexington Avenue, Suite 450 New York, New York	10170
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (212)-584-4180

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

NeoStem, Inc. (the “Company”) is furnishing investor materials, including the presentation and investor letter appearing as exhibits to this report, which will be used by the Company to send to and/or meet with investors.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1	Letter to Investors
Exhibit 99.2	Presentation to Investors

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOSTEM, INC.

By: /s/ Catherine M. Vaczy
Catherine M. Vaczy
Vice President and General Counsel

Dated: January 9, 2008

EXHIBIT INDEX

Exhibit Number	Description
Exhibit 99.1	Letter to Investors
Exhibit 99.2	Presentation to Investors

January 10, 2008

Dear Investor,

If you are interested in an investment opportunity in the rapidly developing stem cell market, then you should know about **NeoStem, Inc. (AMEX: NBS)**.

NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Investment Thesis

The ability of people to readily harvest and store their own stem cells is the backbone of the fast growing area of regenerative medicine. Today, adult stem cells are the standard of care in treating over 40 diseases including bone marrow cancers, such as leukemia, lymphomas, and multiple myelomas. Other diseases such as radiation sickness or bone marrow deficiencies from chemotherapy have successfully been treated as well.

The issues faced by recipients of such therapy is that more often than not they must rely on non-self donors and they thereby can face difficulties in finding a “match,” as well as severe rejection issues. The NeoStem method of self collection and storage, while one is healthy and before his/her stem cells may have had a chance of becoming compromised by disease, solves these issues. Autologous donation is particularly meaningful because approximately 1 in 100 of us will develop one of the 40 aforementioned diseases by the time we are 50.

The future of NeoStem’s autologous stem cell collection and storage business also appears promising. The National Institutes of Health lists more than 1,500 clinical trials currently underway in the US investigating adult stem cell use as potential breakthrough therapies for a myriad of diseases, including, cancer, diabetes, heart and vascular disease, and autoimmune disorders such as lupus, multiple sclerosis and arthritis. More than 500 of these are for autologous use, meaning the stem cells come from your own body for your own use. Frost & Sullivan predicts that the ***market for stem cell therapy worldwide is expected to be $20 billion by 2010***. This is roughly the equivalent of 20 "blockbuster" drugs.

NeoStem is the first company to provide adult stem cell collection and banking services to the general population for their future medical use, and the process it uses is minimally invasive and efficient. Following two shots of a mobilizing agent, adult stem cells are extracted by a blood draw, separated and collected through a relatively painless and safe procedure (with the non-stem cell blood components returned to your bloodstream) and prepared for long-term storage preservation utilizing NeoStem's proprietary methodologies. Individuals may access their stored stem cells in times of future medical need.

Revenue and Business Models

NeoStem generates revenue and earnings through three basic avenues: (1) patient collection fees, (2) processing center collection fees and (3) storage fees, which represent recurring revenue paid each year or month. We have established a relationship with CareCredit, a GE Financial Services Company and the nation's leading patient financing program to assist our patients who wish to pay for our services over time—which we believe opens up a broader client base to us.

During 2007, we were focused on establishing a nationwide network of collection centers in the major metropolitan areas of the US to drive growth, which should allow us to begin generating revenue early in 2008:

- New York Metropolitan Area: The Company signed an agreement to open an adult stem cell collection center with ProHEALTH Care Associates, one of the largest and most prominent multi-specialty practices in the region, with over 100 doctors and 250 patients. The Company also signed an agreement for a New York City facility with WOR Radio Medical Community's Dr. Richard Ash of the Ash Center for Comprehensive Medicine. Subject to the receipt of appropriate licensure, the facilities are expected to open in Q1 2008.

- California and Colorado: The Company signed an agreement with Stem Collect LLC, entitling that entity to open adult stem cell collection facilities, expanding NeoStem's network throughout much of California and launching the Colorado market. One of the California centers is to be in the Beverly Hills environs. NeoStem has an existing facility in Encinitas, California.

- Nevada: The newest adult stem cell collection facility has been opened in Las Vegas, Nevada. The Las Vegas location offers a high level of potential customer traffic (both U.S. and international) and an exciting destination center for those seeking a potentially powerful way to protect their long-term health.

- Northeast Region: The Company expanded its collection network into Pennsylvania in 2007. The Company also formed a strategic alliance with New England Cryogenic Center, Inc. (NECC), one of the largest cryogenic laboratories, to provide extensive processing and storage capacity for consumers on the East Coast.

We have structured our business to be characterized by a high degree of operating leverage, whereby a small number of MDs, performing a modest number of procedures each month, should enable us to reach operating profitability. For example, for demonstration purposes only, if one assumes that NeoStem earns $1,750 per donor and that the Company's overhead approximates $4 million annually, each doctor that joins our network would contribute approximately $20,000 to operating profits each year if it performed one collection per month. In other words, at this assumed collection rate and level of overhead, NeoStem could reach breakeven with only about 200 physicians in our network—just double the number we have in ProHealth alone.

New Opportunities and Potential Value Drivers

In addition to our stem cell collection business, we are expanding our intellectual property portfolio with applications relating to early-stage stem cell technologies for potential therapeutic use. In November 2007, we acquired the exclusive worldwide rights to technology developed by researchers at the University of Louisville involving Very Small Embryonic-Like Stem Cells ("VSELs"), which have been shown to have several physical characteristics generally found in embryonic stem cells.

VSELs have the ability to grow in the laboratory and multiply into clusters of cells that then can differentiate into specialized cells found in different types of tissue including cardiac, neural, endothelial, muscle, pancreatic and hematopoietic cells. However, unlike controversial embryonic stem cells, VSELs can be **harvested from adult peripheral blood**. The significance of VSEL technology is that each of us has a population of very primitive embryonic stem cells that have remained in our bodies since before birth, and should stem cell expansion technology become available, these naturally occurring regenerative cells may have the potential to be used for future therapeutic repair of degenerative, diseased or damaged tissue.

We are also exploring entering the stem cell supply business for research, which we believe has the potential to be a significant business in its own right.

Concluding Remarks

With the enhanced infrastructure, intellectual property portfolio and alliances we have put in place over the past year, we believe NeoStem is well positioned to enter the revenue stage in 2008 and grow even further in the years ahead. The company has 4.8 million primary shares outstanding and a market capitalization that is less than $10 million. Given the opportunities in our marketplace and potential for achieving profitability with a relatively low number of patients, we hope you will find NeoStem to be a compelling investment opportunity and encourage you to learn more about us. For additional information, please visit our website at www.neostem.com, or contact us at 212-584-4180.

Sincerely,

Robin Smith
Chief Executive Officer
NeoStem, Inc.

Forward Looking Statements

Certain statements in this letter constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings." Investors are also reminded that the financial assumptions and information provided under the heading "Revenue and Business Model" are presented for demonstration purposes only and may not bear any relation to among other things, the actual margins, breakeven points, level of operating leverage, individual physician profitability or other inputs that may comprise the metrics upon which NeoStem's actual profitability will be based.

NeoStem™

Investor Overview



Robin Smith, MD, MBA
CEO and Chairman of the Board

(AMEX: NBS)

FORWARD LOOKING STATEMENTS

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings." Investors are also reminded that certain financial assumptions and information contained under "Company Highlights" and "Investment Considerations" are presented for demonstration purposes only and may not bear any relation to among other things, the actual margins, breakeven points, level of operating leverage, individual physician profitability or other inputs that may comprise the metrics upon which NeoStem's actual profitability will be based.

Company Overview*

NeoStem has a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered the research and development and therapeutic arena, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic-like) stem cells which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

*NeoStem's business does not involve use of embryonic stem cells

Company Highlights

- Multiple revenue streams through patient collection fees, processing center collection fees, and storage fees, which represent recurring revenue
- Cumulative recurring revenue stream from storage fees could mean base of 5,000 patients yields approximately $2 million per year in EBIT
- High operating leverage implying breakeven revenue that could be achieved with a small number of physicians joining network (as low as 200)
- One collection per month minimum from each physician yields approximately $20,000 to EBIT
- Intend to enter stem cell supply business for research, which we believe may have the potential to become a significant business in its own right
- Acquisition of proprietary Very Small Embryonic-Like Stem Cells ("VSELs") technology

Agenda

- The Stem Cell Therapy Landscape
- Platform Business
- Why Should a Person Collect Today?
- How Our Platform Differs From Cord Blood Industry
- Our Broad Market
- Recent Events
- Our Business Model
- The Team
- Capital Structure
- Investor Considerations

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Projected U.S. Stem Cell Therapy Sales



Source: Robert Young, RRY Publications, February 2006

70+ Diseases Treated w/Stem Cells

Results for many have been quite encouraging

Heart Disease

"It saved my life... my own stem cells."

BERNIE
Adult Stem Cell Heart Recipient

Lupus

"My Lupus has been in remission for more than 5 years.."

KATHY
Adult Stem Cell Recipient

Multiple Sclerosis

"Stem Cells helped me walk again.."

JANICE
Adult Stem Cell Recipient

Diabetes

"13 out of 14 kids are now off insulin.."

DR. RICHARD BURT
Adult Stem Cell Transplanter, Northwestern Hospital

Scleroderma

"I regained my life again... no more pain"

BRAD
Adult Stem Cell Recipient

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Virtually All Therapeutic Areas

Over 1500 Adult Stem Cell Clinical Trials

Over 500 Specific to Autologous Use

- New Therapies could be on the Market in 5-10 Years
  - Autoimmune
  - Diabetes/Metabolic
  - Cardiovascular
  - Orthopedic

Fracture

2 Months Post BMSC

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

402 Cardiovascular Clinical Trials

One Indication Only!

Institution	Location	No. Sub.	Condition	Length of Study
Helsinki University	Finland	60	Heart Failure	2006-2009
Texas Heart Institute	Houston	60	CAD	2006-2008
Rigshospitalet	Copenhagen	40	Atherosclerosis	2005-2009
Minneapolis Heart Inst.	Minneapolis	60	Recent AMI	N/A
Baxter Healthcare Corp.	Deerfield, IL	150	Angina	N/A
Medical Univ. Of Vienna	Austria	360	Recent AMI	2005-2008
Medical Univ. of Silesia	Poland	200	Recent AMI	2004-2007

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Reference. clinicaltrials.gov

Platform Business

NeoStem has a proprietary, safe and non invasive way for adults to have their stem cells collected today and stored for future use. Our platform will allow doctors and patients ready access to their cells as therapies become available in the future.

Why Collect Today?

- Finding an ostensively "matching" donor is very difficult
- People are dying on the "wait list" (4 mo. avg.)
- Rejection-Graft vs. Host Disease (40% chance even if "perfect" match)
- Risk of transmission of communicable disease
- Possible reluctance to collect and use autologous cells once you are sick because they may have become compromised
- Inverse relationship between age versus quality and quantity of cells
- Financing available from GE contributing to affordability

Banking Your Own Cells with NeoStem
Before You Get Sick Solves these Issues

Intellectual Property

- 4 Patent Applications Pending on Platform Business:
  - Collection of adult stem cells from peripheral blood of healthy individuals for future use to treat various diseases of the individual
  - Process by which NeoStem prepares and stores stem cells collected from peripheral blood by apheresis following mobilization of stem cells from bone marrow
  - Use of stored stem cells to form basis for medical information that provides statistics for etiology of disease
  - NeoStem's low-dose, short course, cytokine induction of stem cell mobilization
- Patent Applications pending on Very Small Embryonic – Like (VSEL) Stem Cell Technology exclusively licensed from the University of Louisville in November 2007:
  - Identification, isolation, and use of population of stem cells isolated from bone marrow, umbilical cord blood, and/or other sources and that are referred to as Very Small Embryonic-Like (VSEL) stem cells

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Our Platform Differs From Cord Blood Industry

CONSIDERATION	CORD BLOOD	NEOSTEM
Time of Collection	Birth	Adulthood
Addressable market	4 million births in US per annum	50+ million in U.S. with diseases where stem cell therapies are used as a currently available treatment or for which stem cell-related clinical trials are in progress
Volume Considerations 	Quantity sufficient until about a child reaching 100Kg or approximately 7 years of age	Quantity sufficient for adults throughout life
Incidence of transplantation and use	Estimate of .1% to .0005% for children	Much greater for adults, especially as disease becomes more prevalent with age and stem cell technology advances
Limitations	Quantity of cells collected is too small and rejection remains an issue Expansion technology not available	NeoStem solves the issues associated with donor cord blood transplants

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

A Broad Target Market

- People with family history of disease
- Patients in a pre-disease or early-disease states
- Parents who have banked their children's cord blood
- First responders
  - military personnel
  - Policemen, firemen, EMS
- Industry (workers facing exposure to radiation/chemicals)

By 2010, it is estimated that 39% of the U.S. population (over 110 mm people) will be 45 years of age or older—a time when the incidence of age-related diseases begins to accelerate.

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Recent Events

- Closed on $6,350,000 in August 2007
- Listed on the American Stock Exchange
- Launched Las Vegas collection center
- Signed multi-center agreement initially to expand on West Coast and Midwest with Stem Collect, LLC founded by James Doty, MD, former CEO of $1B Nasdaq Medical Device Co. Accuray
- Signed agreement for Long Island, New York facility with large physician practice, ProHealth
- Executed collaborative agreement with New England Cryogenic Center, one of the largest cryopreservation facilities in the country for stem cell and other tissue storage
- Signed agreement for New York City facility with WOR Radio Medical Community's Dr. Richard Ash of the Ash Center for Comprehensive Medicine

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Exclusive World Wide VSEL License

Very Small Embryonic-Like (VSELs) Stem Cells

- Each of us has a population of very primitive embryonic like stem cells that have remained dormant in our bodies since birth
  - Can be mobilized in the **blood** using NeoStem Process
  - Should be easily recovered
  - Cryopreserved
  - Used for future therapeutic use

- These autologous cells may prove to be the most abundant and easily recoverable pluripotent adult stem cells in our bodies

- Enriched in the expression of genes found in:
  - Skeletal muscle
  - Heart
  - Neural cells
  - Liver and Pancreas
  - Intestinal and Skin Epithelium

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Our Revenue Model

- **Current:**
  - Collection center fees
  - Collection from patients
  - Processing patient cells
  - Storage (recurring revenue)

- **Potential:**
  - Utilization fees
  - Supplier of stem cells for research
  - Collection fees for trials
  - Government/military contracts
  - SBIR grants
  - Licensing of technology

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Disclaimer: Slide is for Demonstration Purposes Only

EBIT SENSITIVITY

Does not include annual storage



Assumes direct collection profit = $1,750 and breakeven at ~ 2,375 collections. At ~200 MD's in network, BE at 1 collection per month.

Certain assumptions are made solely for the purpose of demonstrating NeoStem's business model. You are cautioned not to place reliance on the Company achieving these assumptions. No assurances can be made as to the level of NeoStem's future profits or that the Company will ever be profitable.

Disclaimer: Slide is for Demonstration Purposes Only

Annual Recurring Revenue

Assumes Collections Abruptly Stop After 5 years (for demonstration purposes)



Assumes storage fee paid for 20 years with EBIT of $500 per collection per annum.

Without arbitrary 5 year assumption curve continues to steepen

Disclaimer: Slide is for Demonstration Purposes Only

EBIT SENSITIVITY

Includes annual storage



Assumes direct collection profit = $1,750 and breakeven at ~ 2,375 collections. At 200 MD's in network, BE at 1 collection per month.

Certain assumptions are made solely for the purpose of demonstrating NeoStem's business model. You are cautioned not to place reliance on the Company achieving these assumptions. No assurances can be made as to the level of NeoStem's future profits or that the Company will ever be profitable.

NeoStem Management & Senior Staff

- **Robin Smith, M.D., MBA,** Chief Executive Officer and Chairman of the Board. Dr. Smith has acted as a senior advisor and investor to both publicly traded and privately held companies where she has played a significant role in restructuring and/or growing the companies. Dr. Smith also serves on the Board of Trustees of the NYU School of Medicine Foundation (becoming the NYU Medical Center Board) and Chairman of the Board of Directors for the New York University Hospital for Joint Diseases and was appointed to the Chemotherapy Foundation Board of Trustees, the New York Theatre Ballet and Choose Living. Prior to these activities, Dr. Smith served as President & Chief Executive Officer of IP2M. During her term, the company was selected as being one of the 10 fastest growing technology companies in Houston.
- **Mark Weinreb,** Director and President. Former Owner, Bio Health Laboratories.
- **Larry A. May,** Chief Financial Officer. Former Treasurer, Amgen (NASDAQ: AMGN).
- **Renee Cohen, MBA,** Vice President. Operations and Corporate Strategy. Formerly held senior executive positions at Pfizer, Co-Founder and Chief Operating Officer of Drugvoice and was a strategic consultant for Accenture's Life Sciences Group.
- **Catherine M. Vaczy,** VP & General Counsel. Former VP and Associate General Counsel, ImClone (NASDAQ: IMCL)
- **Denis Rodgerson, Ph.D.,** Director of Stem Cell Science. Founder of NeoStem, Former Founder of StemCyte, Former Head of Clinical Chemistry and Toxicology and Clinical Laboratory Computing, UCLA Medical Center.
- **George Smith, M.D.,** Medical Director of Laboratory Operations in California. Among his many distinguished career accomplishments, Dr. Smith is cofounder of UCLA Bone Marrow Transplant Center.
- **Arlene Graime**, Director, Government Affairs & Special Projects. Former Senior Director of Marketing at Coach, Inc., served as the National Director of Events for the United States Olympic Committee and worked with key staff members of two White House administrations.
- **Kevin Mannix,** Director of Sales. Former principle manager in sales at Baxter Healthcare, Vested Healthcare Management and Turner Consulting with 27 years of experience in healthcare.

Scientific Advisory Board

- **Wayne A. Marasco, M.D., Ph.D. Chairman -** Chairman of Scientific Advisory Board. Associate Professor-Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He is taking the lead in expanding the Company's academic relationships and research collaborations.

- **Douglas W. Losordo, MD** - For many years a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth's Medical Center in Boston, Dr. Losordo was recently appointed Professor of Medicine at Northwestern University and Director of the Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine. A Fellow or Member of many national professional organizations, he currently serves on committees of the American College of Cardiology, the American Diabetes Association and the American Society of Gene Therapy where he chairs the Cardiovascular Gene Therapy Committee. Dr. Losordo serves as Principal Investigator in many grant research projects and has published widely, contributing to more than 300 professional articles, abstracts and book chapters in recent years. He also serves on the Editorial Boards of numerous medical specialty journals including *Stem Cells*, *Vascular Medicine* and *Circulation Research*.

- **Stephen D. Nimer, MD** - Dr. Nimer is Professor of Medicine and Professor of Pharmacology at Weill Medical College of Cornell University. He also serves as Chief of Hematology Service and Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Nimer is a member of many national professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the International Society for Stem Cell Research. He serves as a Reviewer for major medical journals, including the *New England Journal of Medicine* and the *Journal of the American Medical Association (JAMA)* among many others. He serves on numerous national and international Grant Review Committees and is a prominent invited speaker at conferences on his areas of expertise. He has authored or co-authored nearly 200 peer-reviewed papers, reviews, editorials and textbook chapters, primarily focused on issues concerning hematology and oncology.

Advisory Board

• **Ron Rothenberg MD, FACEP** - Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certified by the American Board of Anti-Aging Medicine. A graduate of Columbia University, College of Physicians and Surgeons, and a specialist in Emergency Medicine at Los Angeles County-USC Medical Center, he has served as Clinical Professor of Preventive and Family Medicine at the UCSD School of Medicine Clinical Facility. He is currently Attending Physician at Scripps Memorial Hospital in Encinitas.

• **Richard Gatti, MD** - Dr. Richard Gatti, a professor at the University of California, Los Angeles (UCLA) and renowned Pathologist at the UCLA Medical Center, was one of the early pioneers of bone marrow transplantation, among the earliest known forms of adult stem cell therapeutics, for immunodeficiency in the late sixties. Dr. Gatti is also a leading authority in the field of gene therapeutics and has authored or co-authored hundreds of papers related to the molecular identification and treatment of genetic disorders. He has worked for many years to help find a cure for Ataxia-Telangiectasia, a progressive neurological disorder of childhood, associated with increased cancer risk, immunodeficiency, radiosensitivity, and cell cycle defects.

• **Neil Livingstone, PhD** - Dr. Livingstone is currently the Chairman and Chief Executive Officer of ExecutiveAction LLC. He was the founder and, until January, 2007, Chief Executive Officer of GlobalOptions Inc., which went public in 2005. He is also Lead Director of Erickson Air-Crane, a $200 million helicopter company. Dr. Livingstone has noted expertise on national security, and is the author of nine books on terrorism. He has served on advisory panels to The Secretary of State, The Chief of Naval Operations, and The Pentagon. He has testified before Congress and delivered more than 500 major addresses in the U.S. and abroad, including recent speeches at The House of Commons and The United Nations. Dr. Livingstone serves on numerous advisory boards, including Supercom Inc., Digital Ally, the Africa Society, and No Greater Love. He was the Founder and Chairman of the Institute on Terrorism and Sub-national Conflict and served as President of Watergate South for more than seven years.

• **Bradford Billet, OBE CEM -** Mr. Billet is an executive with the City of New York, where his responsibilities include matters of international affairs, security and emergency management. He is also chairman of the Billet Group, a management consulting company. During the past 20 plus years, Mr. Billet has acquired extensive experience in International Affairs, Emergency Management, Security, Governmental and Business Management, Administration and Operational disciplines. He has held high-ranking positions in both the private and public sectors with budgets in excess of 180 million dollars. Mr. Billet has responded, coordinated and directed multi agency emergency operations, including the September 11th attacks and the 1993 bombing of the World Trade Center, 20 aviation accidents as well as numerous manmade and natural disasters, involving mass casualties and/or fatalities.

• **Douglas Wynyard -** Mr. Douglas Wynyard is a Senior Vice President for Nordblom Company, a full-service commercial real estate firm headquartered in the Boston area. He is experienced in real estate development, asset management, leasing, investment sales, and marketing. He also represents numerous corporations with the planning, acquisition and disposition of their facilities. Having received a Bachelor's degree in Zoology from Bristol University, Mr. Wynyard is passionate about the biological sciences and is an investor in a number of medtech companies.

Capitalization

At January 7, 2007		
	Shares	
Common Stock	4,879,237	
Stock Options	1,141,300	Weighted average exercise price = $5.68
Warrants	2,087,938	Weighted average exercise price = $7.04
Fully Diluted Ownership	8,108,475	
NBS Price Per Share:	$1.55	
Market Capitalization	$7.56 million	
Stock Symbol (AMEX)	NBS	
Warrant Symbol (AMEX)	NBS.WS	

NeoStem
YOUR CELLS. YOUR USE. YOUR LIFE.

Investment Considerations

- Exponential potential earnings leverage with small number of physicians joining network (approximately 200)
    - 1 collection per month minimum from each physician is projected to yield approximately $20,000 per year to EBIT, 5 collections per month is projected to yield approximately $100,000 per year to EBIT
- Cumulative recurring revenue stream from storage fees could mean base of 5,000 patients yields approximately $2 million per year in EBIT
- Potential licensing avenues for proprietary Very Small Embryonic-Like Stem Cells ("VSELs") technology
- PerkinElmer/Viacell ($300 million acquisition)
- Intend to enter stem cell supply business for research, which has potential to become a significant business in its own right
- Company believes current market cap significantly undervalues infrastructure in place and near-term earnings visibility

Questions

Robin Smith, MD MBA
Chairman & CEO
Direct: (212) 584-4174
Email: rsmith@neostem.com

NeoStem, Inc.
420 Lexington Avenue
Suite 450
New York, NY 10170
Main: (212) 584-4180
Fax: (646) 514-7787
www.neostem.com
1.888.STEM BANK